AstraZeneca Wants to Conceal Seroquel Information
Pharmaceutical companies willingly settle court cases for hundreds of millions of dollars–even billions of dollars–to keep the truth about their drugs under seal.
-
-
Rolling Stone – Marketing a Phony “Miracle” Drug
“Bitter Pill” by Ben Wallace-Wells in the current issue of Rolling Stone is an excellent, informative, in-depth article providing an overview into the pharmaceutical industry’s immensely successful—albeit illegal—aggressive marketing tactics, for selling a particularly unsafe, dangerous class of drugs—the antipsychotics, Zyprexa in particular.
-
America’s Medicated Army + New Studies Linking SSRI to Suicide
Using drugs to cope with battlefield traumas is not discussed much outside the Army, but inside the service it has been the subject of debate for years.
-
Marcia Angell: Drug Co & Doctors: A Story of Corruption
"It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine." Marcia Angell, MD
-
Biederman J & J Risperdal Documents
A group of internal emails by Johnson & Johnson officials-mostly from officials in the company’s Risperdal marketing division-provide a bird’s eye view of collusion between the drug giant and Harvard’s leading child psychiatrist, Dr. Joseph Biederman, and one of Harvard’s premier teaching hospitals, Massachusetts General Hospital.
-
Antipsychotic Use in Children: FDA Panel Rejects FDA Soft-Peddle Approach
"The committee’s concerns are part of a growing chorus of complaints about the increasing use of antipsychotic medicines in children and teenagers.
-
Vera Sharav: A Profile in Nature Biotechnology
Dr. Marcia Angell, a senior lecturer at Harvard Medical School, and former editor of the New England Journal of Medicine and author of The Truth About Drug Companies, describes Sharav as an extraordinarily observant and valuable critic. "I see her as someone the research establishment badly needs."
-
Letter of Complaint Re: FDA Double Agent
A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels.
-
Letter of Complaint to FDA Commissioner, 2007
Complaint about a surge of FDA administrative approvals for expanded use of highly toxic antipsychotic drugs for children. Approvals were determined by Dr. Thomas Laughren after secret deliberations–without disclosure of scientific data, without an advisory panel or open public discussion.
-
FDA Internal Document: Use of Placebo-Controls in Life Threatening Diseases
The efficacy and safety of a new drug that treats a serious and life threatening illness in premature infants will be studied versus sham/placebo in Latin America. The sponsor plans to apply for FDA approval, in addition to local and European registration. There are approved therapies (surfactants) for this illness (Respiratory Distress Syndrome, or RDS) in those countries where this trial is proposed to take place, and surfactants are even used in some of their hospitals. However, surfactants are completely unavailable to infants at many other hospitals, secondary to rationing or economic limitations.
-
Use of Placebo-Controls in Life Threatening Diseases
FDA Considers: Use of Placebo-Controls in Life Threatening Diseases: Is the Developing World the Answer? The efficacy and safety of a new drug that treats a serious and life threatening illness in premature infants will be studied versus sham / placebo in Latin America.
-
A Response to Dr. Richard Friedman’s Defense of TeenScreen
Dr. Karen Effrem refutes Dr Friedman who claims there is "a silent epidemic of mental illness among teenagers."
